

Extramural Activities, National Institute of Mental Health, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Rockville, MD 20892, 305-586-9937, claudio.ortiz@nih.gov.

Name of Committee: National Institute of Mental Health Special Emphasis Panel; BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00).

Date: June 22, 2023.

Time: 11:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Emma Perez-Costas, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Rockville, MD 20892, 301-827-9275, emma.perez-costas@nih.gov.

(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)

Dated: May 17, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-10930 Filed 5-22-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Amend Notice of Meeting

Notice is hereby given of a change in the meeting of the National Heart, Lung, and Blood Institute Special Emphasis Panel, June 6, 2023, 1 p.m. to 5 p.m., National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD, 20892 which was published in the **Federal Register** on May 15, 2023, FR Document No. 2023-10224, 88 FRN 30997.

This notice is being amended to correct the June 6, 2023 meeting title that was published as "The National Heart, Lung, and Blood Institute Special Emphasis Panel SPECIAL EMPHASIS PANEL". The correct title is "The National Heart, Lung, and Blood Institute Special Emphasis Panel NRSA Member Conflict Panel". The meeting is closed to the public.

Dated: May 18, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-10936 Filed 5-22-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Request for Information on the Prioritization of Drug, Vaccine, and Dietary Supplement Research Needs for Pregnant, Postpartum, and Lactating Persons

AGENCY: National Institutes of Health, HHS.

ACTION: Request for information.

SUMMARY: The National Institute of Child Health and Human Development (NICHD) seeks nominations for drug, vaccine, and dietary supplement research needs to be considered in the development of a Priority List of Drug, Vaccine, and Dietary Supplement Research Needs for Pregnant, Postpartum, and Lactating Persons. The NICHD is gathering nominations for drugs prescribed for conditions specific to or that co-occur during pregnancy and the postpartum period, including for lactation; dietary supplements that may be used in preparation for, during, or after pregnancy; and vaccines used by pregnant or lactating persons to prevent or treat disease. Additionally, the NICHD is seeking information on factors and processes it could consider in prioritizing these nominations. Nominations are requested from public and private stakeholders such as, but not limited to, researchers, academia, small- and large-scale industries, non-profit organizations, patients, providers, advocacy groups, payors, and federal agencies.

DATES: The request for information is open for public comment and will be accepted through September 29, 2023.

ADDRESSES: Submissions must be submitted via a survey using the following link: <https://www.surveymonkey.com/r/PRGLAC23>.

FOR FURTHER INFORMATION CONTACT: Questions about this request for information should be directed to Camille Fabiyi, Ph.D., MPH, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Dr., Bethesda, MD 20892, NICHD-PRGLAC@mail.nih.gov, 301-496-3916.

SUPPLEMENTARY INFORMATION: This RFI is intended to obtain information to help advance recommendations outlined in the 2018 Report of the Task Force for Research Specific to Pregnant and Lactating Women (PRGLAC) and 2020 PRGLAC Implementation Plan. In 2016, Congress established PRGLAC through

the 21st Century Cures Act to advise the Secretary of Health and Human Services (HHS) regarding gaps in knowledge and research on safe and effective therapies for pregnant and lactating persons. The PRGLAC task force was charged with providing advice and guidance to the HHS Secretary on activities related to identifying and addressing gaps in knowledge and research on safe and effective therapies for pregnant and lactating persons, including the development of such therapies and the collaboration on and coordination of such activities.

The task force developed 15 recommendations based on information gleaned during four open meetings and a request for public comments. The recommendations were submitted in the PRGLAC Report to the HHS Secretary and Congress in September 2018. The report recommended that pregnant and lactating persons be included in the clinical research agenda. The task force published a PRGLAC Implementation Plan in August 2020. A comprehensive review of research conducted for the task force deliberations clearly showed the extremely limited information available on medication use in pregnancy and lactation. Evidence-based answers are required for pregnant and lactating persons and their clinicians to make fully informed choices based on the risks and benefits of medicating or not medicating conditions during pregnancy and lactation. The provision of clinical data is essential to increasing the quantity, quality, and timeliness of research on safety and efficacy of therapeutic products used by pregnant, postpartum, and lactating persons.

Most women use at least one medication during pregnancy and the postpartum period. Many women who become pregnant or are lactating already have chronic conditions needing treatment, in addition to conditions that may arise as a result of pregnancy or lactation. Consequently, because so few studies have been conducted, some prioritization is necessary to determine which drugs, vaccines, and dietary supplements should be studied first.

Information Requested

The NICHD seeks information and actionable recommendations on research gaps and needs as potential priorities for drugs, vaccines, and dietary supplements used by pregnant, postpartum, or lactating persons.

Comments are strongly encouraged to address challenges and knowledge gaps around drugs, vaccines, or dietary supplements used during pregnancy, the postpartum period, or lactation on